ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
글루카곤 유사 펩타이드 1(GLP-1) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 220억 6,000만 달러에서 2026년에는 238억 8,000만 달러로, CAGR 8.2%로 확대될 전망입니다. 지난 수년간의 성장에는 당뇨병 유병률 증가, 전 세계 비만율 증가, 주사제 펩타이드 치료의 수용 확대, 내분비 치료 옵션의 확대, 브랜드 GLP-1 약물의 보급 등이 주요 요인으로 작용한 것으로 보입니다.
글루카곤 유사 펩타이드 1(GLP-1) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 332억 6,000만 달러에 달하고, CAGR은 8.6%가 될 전망입니다. 예측 기간의 성장 요인으로는 체중 관리 요법에 대한 수요 증가, 펩타이드 의약품 혁신에 대한 투자 확대, 경구용 펩타이드 전달 기술의 발전, 만성질환 관리에 대한 관심 증가, 맞춤형 의료의 보급 확대 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 비만 관리에서 GLP-1 요법의 채택 증가, 경구용 GLP-1 제제의 개발 진전, 지속형 펩타이드 의약품에 대한 관심 증가, 병용요법 접근법 확대, 환자 중심의 약물전달 시스템 강화 등을 들 수 있습니다.
맞춤형 의료에 대한 관심이 높아지면서 향후 몇 년 동안 글루카곤 유사 펩타이드 1(GLP-1) 시장의 성장을 견인할 것으로 예상됩니다. 개인맞춤의료는 개인의 유전자 및 단백질에 대한 지식을 활용하여 질병을 예방, 감지, 치료하는 접근법입니다. 이를 통해 각 환자의 특정 필요와 선호도에 따라 GLP-1 제형과 용량을 맞춤화할 수 있습니다. 예를 들어, 2024년 2월 미국 비영리단체 '맞춤의료연합'이 발표한 바에 따르면, 2023년 FDA가 승인한 희귀질환 환자를 위한 신규 맞춤치료제는 16건으로 2022년 6건보다 증가하였다고 합니다. 2023년 승인 품목에는 암 치료제 7건과 기타 질환 및 증상 치료제 3건도 포함되어 있습니다. 이처럼 맞춤형 의료에 대한 관심이 높아지면서 GLP-1 시장 확대에 기여하고 있습니다.
글루카곤 유사 펩타이드 1(GLP-1) 시장의 주요 기업들은 당뇨병 치료 및 체중 관리의 치료 효과, 안전성, 환자 편의성 향상을 위한 기술 혁신을 우선적으로 추진하고 있습니다. GLP-1 요법은 체내 천연 GLP-1 호르몬의 작용을 모방하여 식욕, 당대사, 체중을 조절하는 주사 가능한 펩타이드 계열의 약물입니다. 예를 들어, 2024년 3월 덴마크 제약사 노보노디스크는 세계 최초이자 유일한 주 1회 투여형 GLP-1 치료제 '웨고비'를 출시했습니다. STEP 3a상 임상시험 프로그램을 통해 개발된 웨고비는 안전성과 우수한 내약성을 입증했으며, 비만 환자의 체중감량 달성 및 유지에 도움을 주는 것을 목표로 하고 있습니다. 웨고비는 주 1회 투약이라는 편의성을 제공함으로써 환자들의 복약 순응도를 높이고, 혁신적이고 효과적인 비만 치료제에 대한 수요 증가에 대응할 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 시장에서 세계의 총 잠재 시장 규모(TAM)
제9장 시장 세분화
제10장 지역별·국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자 환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업과 혁신적 기업
제38장 세계의 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
KSM
영문 목차
영문목차
Glucagon-like peptide 1 (GLP-1) is a peptide hormone derived from amino acids and produced in the L-cells of the intestinal epithelial endocrine. This hormone is employed in the treatment of diseases such as diabetes and obesity.
The primary product types of glucagon-such as peptide 1 include Trulicity, Ozempic, Victoza, Rybelsus, and others. Trulicity, a prescription medicine administered through injection, is designed to enhance blood sugar levels. Various routes of administration, including oral, parenteral, and others, are utilized in settings such as hospitals, specialty clinics, and more.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Tariffs are influencing the glucagon-like peptide 1 market by increasing costs of imported active pharmaceutical ingredients, peptide synthesis equipment, injection devices, and specialized packaging materials. North America and Europe are most affected due to dependence on global pharmaceutical supply chains, while Asia-Pacific faces cost pressures in export-oriented drug manufacturing. These tariffs are raising production and distribution costs. However, they are also encouraging localized drug manufacturing, regional API production, and strategic partnerships to strengthen domestic pharmaceutical capabilities.
The glucagon-like peptide 1 market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide 1 market statistics, including glucagon-like peptide 1 industry global market size, regional shares, competitors with a glucagon-like peptide 1 market share, detailed glucagon-like peptide 1 market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide 1 industry. This glucagon-like peptide 1 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $22.06 billion in 2025 to $23.88 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of diabetes, rising obesity rates globally, growing acceptance of injectable peptide therapies, expansion of endocrinology treatment options, availability of branded glp-1 drugs.
The glucagon-like peptide 1 market size is expected to see strong growth in the next few years. It will grow to $33.26 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing demand for weight management therapies, rising investments in peptide drug innovation, expansion of oral peptide delivery technologies, growing focus on chronic disease management, increasing adoption of personalized medicine. Major trends in the forecast period include rising adoption of GLP-1 therapies for obesity management, increasing development of oral glp-1 formulations, growing focus on long-acting peptide drugs, expansion of combination therapy approaches, enhanced patient-centric drug delivery systems.
Increasing focus on personalized medicine is anticipated to drive the growth of the glucagon-like peptide 1 (GLP-1) market in the coming years. Personalized medicine involves using knowledge of an individual's genes or proteins to prevent, detect, or treat diseases. It enables the customization of GLP-1 formulations and dosages according to each patient's specific needs and preferences. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared to six in 2022. The 2023 approvals also included seven cancer drugs and three treatments for other diseases and conditions. This growing emphasis on personalized medicine is thus contributing to the expansion of the GLP-1 market.
Key players in the glucagon-like peptide 1 market are prioritizing technological advancements to improve therapeutic effectiveness, safety, and patient convenience in diabetes care and weight management. GLP-1 therapies are injectable peptide-based drugs that replicate the activity of the body's natural GLP-1 hormone to regulate appetite, glucose metabolism, and body weight. For instance, in March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly GLP-1 therapy for weight management. Developed through the STEP Phase 3a clinical trial program, Wegovy demonstrated a safe and well-tolerated profile and is intended to help individuals with obesity achieve and maintain weight loss. By offering a convenient weekly dosing schedule, Wegovy improves patient adherence and addresses the rising demand for innovative and effective obesity treatments.
In March 2024, Novo Holdings A/S, an investment company based in Denmark, acquired Catalent Inc. for $16.5 billion. This acquisition is intended to enhance Novo Holdings' presence in the rapidly growing GLP-1 market by utilizing Catalent's established infrastructure in fill-finish manufacturing. This move aims to increase capacity to meet the rising demand for treatments related to diabetes and weight loss. Catalent Inc. is a biotechnology company located in the United States that specializes in advanced delivery technologies and development solutions for pharmaceuticals.
Major companies operating in the glucagon-like peptide 1 market are Novo Nordisk, Eli Lilly And Company, Pfizer Inc., AstraZeneca Plc, Sanofi S.A., Boehringer Ingelheim International GmbH, Merck And Co., Inc., Takeda Pharmaceutical Company Limited, Roche Holding AG, Johnson And Johnson, Amgen Inc., GlaxoSmithKline Plc, Novartis AG, Bayer AG, AbbVie Inc., Bristol Myers Squibb Company, Biocon Limited, Hanmi Pharmaceutical Co., Ltd., Innovent Biologics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Zealand Pharma A/S, Gan And Lee Pharmaceuticals Co., Ltd.
North America was the largest region in the glucagon-like peptide 1 market in 2025. The regions covered in the glucagon-like peptide 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the glucagon-like peptide 1 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The glucagon-such as peptide 1 market consists of sales of dulaglutide, albiglutide, semaglutide, and tirzepatide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glucagon-like Peptide 1 Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses glucagon-like peptide 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for glucagon-like peptide 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glucagon-like peptide 1 market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Product: Trulicity; Ozempic; Victoza; Rybelsus; Other Types
2) By Route of Administration: Oral; Parenteral; Other Routes
3) By End-Users: Hospitals; Specialty Clinics; Other End Users
Subsegments:
1) By Trulicity: Injection (pre-filled pen); Dosage forms (0.75 mg; 1.5 mg; etc.)
2) By Ozempic: Injection (pre-filled pen); Dosage forms (0.5 mg; 1 mg; etc.)
3) By Victoza: Injection (pre-filled pen); Dosage forms (1.2 mg; 1.8 mg; etc.)
4) By Rybelsus: Oral tablet (3 mg; 7 mg; 14 mg)
5) By Other Types: Experimental formulations; Combination products with other medications; Alternative delivery systems
Companies Mentioned: Novo Nordisk; Eli Lilly And Company; Pfizer Inc.; AstraZeneca Plc; Sanofi S.A.; Boehringer Ingelheim International GmbH; Merck And Co., Inc.; Takeda Pharmaceutical Company Limited; Roche Holding AG; Johnson And Johnson; Amgen Inc.; GlaxoSmithKline Plc; Novartis AG; Bayer AG; AbbVie Inc.; Bristol Myers Squibb Company; Biocon Limited; Hanmi Pharmaceutical Co., Ltd.; Innovent Biologics, Inc.; Jiangsu Hengrui Pharmaceuticals Co., Ltd.; Zealand Pharma A/S; Gan And Lee Pharmaceuticals Co., Ltd.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Adoption Of Glp-1 Therapies For Obesity Management
4.2.2 Increasing Development Of Oral Glp-1 Formulations
4.2.3 Growing Focus On Long-Acting Peptide Drugs
4.2.4 Expansion Of Combination Therapy Approaches
4.2.5 Enhanced Patient-Centric Drug Delivery Systems
5. Glucagon-like Peptide 1 Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Diabetes Care Centers
5.4 Pharmaceutical Companies
5.5 Research And Academic Institutes
6. Glucagon-like Peptide 1 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Glucagon-like Peptide 1 Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Glucagon-like Peptide 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Glucagon-like Peptide 1 Market Size, Comparisons And Growth Rate Analysis
7.3. Global Glucagon-like Peptide 1 Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Glucagon-like Peptide 1 Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Glucagon-like Peptide 1 Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Glucagon-like Peptide 1 Market Segmentation
9.1. Global Glucagon-like Peptide 1 Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Trulicity, Ozempic, Victoza, Rybelsus, Other Types
9.2. Global Glucagon-like Peptide 1 Market, Segmentation By Route of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Parenteral, Other Routes
9.3. Global Glucagon-like Peptide 1 Market, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Other End Users
9.4. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Trulicity, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injection (pre-filled pen), Dosage forms (0.75 mg, 1.5 mg, etc.)
9.5. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Ozempic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injection (pre-filled pen), Dosage forms (0.5 mg, 1 mg, etc.)
9.6. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Victoza, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Injection (pre-filled pen), Dosage forms (1.2 mg, 1.8 mg, etc.)
9.7. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Rybelsus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral tablet (3 mg, 7 mg, 14 mg)
9.8. Global Glucagon-like Peptide 1 Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Experimental formulations, Combination products with other medications, Alternative delivery systems
10. Glucagon-like Peptide 1 Market Regional And Country Analysis
10.1. Global Glucagon-like Peptide 1 Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Glucagon-like Peptide 1 Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Glucagon-like Peptide 1 Market
12.1. China Glucagon-like Peptide 1 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Glucagon-like Peptide 1 Market
13.1. India Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Glucagon-like Peptide 1 Market
14.1. Japan Glucagon-like Peptide 1 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Glucagon-like Peptide 1 Market
15.1. Australia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Glucagon-like Peptide 1 Market
16.1. Indonesia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Glucagon-like Peptide 1 Market
17.1. South Korea Glucagon-like Peptide 1 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Glucagon-like Peptide 1 Market
19.1. South East Asia Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Glucagon-like Peptide 1 Market
20.1. Western Europe Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Glucagon-like Peptide 1 Market
21.1. UK Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Glucagon-like Peptide 1 Market
22.1. Germany Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Glucagon-like Peptide 1 Market
23.1. France Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Glucagon-like Peptide 1 Market
24.1. Italy Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Glucagon-like Peptide 1 Market
25.1. Spain Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Glucagon-like Peptide 1 Market
26.1. Eastern Europe Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Glucagon-like Peptide 1 Market
27.1. Russia Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Glucagon-like Peptide 1 Market
28.1. North America Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Glucagon-like Peptide 1 Market
29.1. USA Glucagon-like Peptide 1 Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Glucagon-like Peptide 1 Market
31.1. South America Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Glucagon-like Peptide 1 Market
32.1. Brazil Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Glucagon-like Peptide 1 Market
33.1. Middle East Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Glucagon-like Peptide 1 Market
34.1. Africa Glucagon-like Peptide 1 Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Glucagon-like Peptide 1 Market, Segmentation By Product, Segmentation By Route of Administration, Segmentation By End-Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Glucagon-like Peptide 1 Market Regulatory and Investment Landscape
36. Glucagon-like Peptide 1 Market Competitive Landscape And Company Profiles
